STOCK TITAN

Lifemd, Inc. Financials

LFMDP
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Lifemd, Inc. (LFMDP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LFMDP FY2025

Revenue growth is finally outrunning overhead, but reported profit still depends on below-operating-line items rather than core earnings.

FY2025's 7.4% net margin looks better than FY2024, but the core business still posted a -4.0% operating margin. That gap means the first profitable year was helped by below-operating-line items, so statutory earnings improved faster than the underlying operating engine.

The clearest operating shift is fixed-cost absorption: selling and administrative expense stayed near $57.9M while revenue reached $194.1M, so more gross profit finally covered overhead instead of simply funding more spending. That is why operating losses narrowed even though gross margin eased slightly, pointing to scale rather than a richer sales mix as the main improvement driver.

The balance sheet also became materially less stretched: total liabilities fell to $47.3M from $83.7M, turning equity positive again without relying on a larger cash pile. But cash conversion softened as free cash flow dropped to $6.4M from $16.0M, so the company is healthier financially even as cash generation became less robust than the income-statement headline suggests.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 47 / 100
Financial Profile 47/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lifemd, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
5

Lifemd, Inc. has an operating margin of -4.0%, meaning the company retains $-4 of operating profit per $100 of revenue. This below-average margin results in a low score of 5/100, suggesting thin profitability after operating expenses. This is up from -13.2% the prior year.

Growth
55

Lifemd, Inc.'s revenue surged 25.3% year-over-year to $194.1M, reflecting rapid business expansion. This strong growth earns a score of 55/100.

Leverage
60

Lifemd, Inc. has a moderate D/E ratio of 2.04. This balance of debt and equity financing earns a leverage score of 60/100.

Liquidity
20

Lifemd, Inc.'s current ratio of 1.25 is below the typical benchmark, resulting in a score of 20/100. However, the company holds substantial cash reserves (88% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow
40

Lifemd, Inc. has a free cash flow margin of 3.3%, earning a moderate score of 40/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
100

Lifemd, Inc. earns a strong -48.6% return on equity (ROE), meaning it generates $-49 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.

Piotroski F-Score Neutral
4/9

Lifemd, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed
-0.74x

For every $1 of reported earnings, Lifemd, Inc. generates $-0.74 in operating cash flow ($8.3M OCF vs -$11.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk
-5.6x

Lifemd, Inc. earns $-5.6 in operating income for every $1 of interest expense (-$7.7M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$194.1M
YoY+25.3%
5Y CAGR+39.1%
10Y CAGR+66.0%

Lifemd, Inc. generated $194.1M in revenue in fiscal year 2025. This represents an increase of 25.3% from the prior year.

EBITDA
-$6.7M
YoY+66.3%

Lifemd, Inc.'s EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 66.3% from the prior year.

Net Income
-$11.2M
YoY-145.9%

Lifemd, Inc. reported -$11.2M in net income in fiscal year 2025. This represents a decrease of 145.9% from the prior year.

EPS (Diluted)
$0.25
YoY+141.7%

Lifemd, Inc. earned $0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 141.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$6.4M
YoY-60.1%

Lifemd, Inc. generated $6.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 60.1% from the prior year.

Cash & Debt
$36.8M
YoY+5.1%
5Y CAGR+32.0%
10Y CAGR+65.9%

Lifemd, Inc. held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
47M
YoY+10.6%
5Y CAGR+14.9%

Lifemd, Inc. had 47M shares outstanding in fiscal year 2025. This represents an increase of 10.6% from the prior year.

Margins & Returns

Gross Margin
85.7%
YoY-0.4pp
5Y CAGR+9.5pp
10Y CAGR+6.0pp

Lifemd, Inc.'s gross margin was 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.

Operating Margin
-4.0%
YoY+9.2pp
5Y CAGR+151.1pp
10Y CAGR+17.6pp

Lifemd, Inc.'s operating margin was -4.0% in fiscal year 2025, reflecting core business profitability. This is up 9.2 percentage points from the prior year.

Net Margin
-5.8%
YoY-21.6pp
5Y CAGR+151.5pp
10Y CAGR-0.7pp

Lifemd, Inc.'s net profit margin was -5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.6 percentage points from the prior year.

Return on Equity
-48.6%
10Y CAGR+13.4pp

Lifemd, Inc.'s ROE was -48.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending
N/A
Share Buybacks
$270K

Lifemd, Inc. spent $270K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures
$1.9M
YoY+27.8%

Lifemd, Inc. invested $1.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.8% from the prior year.

LFMDP Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $50.2M+146.8% $20.3M-66.2% $60.2M-4.0% $62.7M+23.2% $50.9M+654.4% $6.7M-87.3% $53.3M+5.2% $50.7M
Cost of Revenue $5.9M+25.0% $4.7M-36.0% $7.4M-0.3% $7.4M-8.7% $8.1M+19.6% $6.8M+35.7% $5.0M-0.2% $5.0M
Gross Profit $44.2M+183.9% $15.6M-70.5% $52.8M-4.5% $55.2M+29.2% $42.8M+75774.3% -$56K-100.1% $48.3M+5.7% $45.6M
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $15.2M+60.7% $9.4M-43.1% $16.6M-5.6% $17.6M+22.5% $14.3M+138.8% $6.0M-66.8% $18.1M-2.2% $18.5M
Operating Income -$8.9M-119.5% -$4.1M-106.5% -$2.0M-336.1% -$452K+61.8% -$1.2M+69.9% -$3.9M+1.7% -$4.0M+36.6% -$6.3M
Interest Expense -$56K-100.6% -$28K-110.7% $262K-60.4% $663K+43.0% $464K-23.7% $608K+8.8% $559K+5.1% $531K
Income Tax N/A N/A $169K N/A N/A N/A $233K N/A
Net Income -$8.9M-57.4% -$5.6M-48.1% -$3.8M-135.0% -$1.6M-781.3% -$184K-100.4% $42.8M+1019.2% -$4.7M+32.3% -$6.9M
EPS (Diluted) $-0.20 N/A $-0.10-100.0% $-0.05-150.0% $-0.02 N/A $-0.13+31.6% $-0.19

LFMDP Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $70.1M-0.4% $70.4M+6.7% $66.0M-10.3% $73.6M-0.1% $73.6M-3.3% $76.1M+4.9% $72.6M+13.7% $63.8M
Current Assets $51.7M-0.3% $51.8M+26.2% $41.1M-16.2% $49.0M-1.9% $50.0M-4.6% $52.4M+7.6% $48.7M+8.0% $45.1M
Cash & Equivalents $34.5M-6.3% $36.8M+54.7% $23.8M-34.3% $36.2M+5.3% $34.4M-1.7% $35.0M-6.9% $37.6M+5.3% $35.7M
Inventory $3.2M+14.6% $2.8M-19.2% $3.4M+5.6% $3.3M+9.6% $3.0M+6.1% $2.8M+5.7% $2.6M+28.4% $2.1M
Accounts Receivable $9.9M+5.9% $9.3M+0.7% $9.2M+26.1% $7.3M-28.1% $10.2M-2.5% $10.5M+72.8% $6.0M+6.7% $5.7M
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $55.1M+16.6% $47.3M-24.5% $62.6M-14.4% $73.2M-1.1% $74.0M-11.5% $83.7M+6.5% $78.5M+19.2% $65.9M
Current Liabilities $49.6M+19.3% $41.6M-26.6% $56.7M-10.8% $63.5M+4.3% $60.9M-9.6% $67.4M+14.3% $59.0M+14.1% $51.6M
Long-Term Debt N/A N/A N/A $15.9M N/A N/A N/A N/A
Total Equity $15.0M-35.1% $23.2M+1661.8% $1.3M+173.7% -$1.8M+23.5% -$2.3M+74.4% -$9.1M-17.7% -$7.7M-83.5% -$4.2M
Retained Earnings -$238.3M-4.2% -$228.6M+7.7% -$247.8M-3.9% -$238.5M-1.2% -$235.6M+1.8% -$239.9M-1.9% -$235.4M-2.6% -$229.5M

LFMDP Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow $445K+113.6% -$3.3M-2129.6% -$147K-101.7% $8.6M+181.6% $3.1M+185.9% $1.1M-84.0% $6.7M+47.5% $4.5M
Capital Expenditures $105K-32.3% $155K-80.5% $797K-0.4% $800K+580.9% $118K-40.6% $198K-55.8% $448K-30.3% $642K
Free Cash Flow $339K+109.9% -$3.4M-263.8% -$944K-112.0% $7.8M+165.7% $3.0M+237.1% $875K-86.0% $6.3M+60.4% $3.9M
Investing Cash Flow -$2.1M-112.0% $17.1M+574.9% -$3.6M+2.8% -$3.7M-29.0% -$2.9M-5.4% -$2.7M+22.1% -$3.5M-11.5% -$3.1M
Financing Cash Flow -$696K+11.7% -$789K+90.9% -$8.7M-180.2% -$3.1M-282.1% -$813K+13.1% -$935K+29.2% -$1.3M-62.0% -$815K
Dividends Paid $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K0.0% $777K
Share Buybacks N/A N/A $270K N/A N/A N/A N/A N/A

LFMDP Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin 88.2%+11.5pp 76.7%-11.0pp 87.7%-0.4pp 88.1%+4.1pp 84.0%+84.8pp -0.8%-91.4pp 90.6%+0.5pp 90.1%
Operating Margin -17.8%+2.2pp -20.0%-16.7pp -3.3%-2.6pp -0.7%+1.6pp -2.3%+55.9pp -58.2%-50.7pp -7.5%+5.0pp -12.4%
Net Margin -17.7%+10.1pp -27.8%-21.4pp -6.3%-3.7pp -2.6%-2.2pp -0.4%-635.1pp 634.7%+643.5pp -8.7%+4.8pp -13.6%
Return on Equity -59.0%-145.2pp 86.2%+375.8pp -289.6% N/A N/A N/A N/A N/A
Return on Assets -12.7%-4.6pp -8.0%-2.2pp -5.8%-3.6pp -2.2%-1.9pp -0.3%-56.5pp 56.3%+62.7pp -6.4%+4.4pp -10.8%
Current Ratio 1.04-0.2 1.25+0.5 0.73-0.0 0.77-0.0 0.82+0.0 0.78-0.0 0.83-0.0 0.87
Debt-to-Equity 3.66+1.6 2.04-45.6 47.64+56.6 -8.92+22.9 -31.78-22.6 -9.21+1.0 -10.17+5.5 -15.66
FCF Margin 0.7%+17.6pp -16.9%-15.3pp -1.6%-14.1pp 12.5%+6.7pp 5.8%-7.2pp 13.0%+1.2pp 11.7%+4.0pp 7.7%

Similar Companies

Frequently Asked Questions

Lifemd, Inc. (LFMDP) reported $194.1M in total revenue for fiscal year 2025. This represents a 25.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Lifemd, Inc. (LFMDP) revenue grew by 25.3% year-over-year, from $154.8M to $194.1M in fiscal year 2025.

No, Lifemd, Inc. (LFMDP) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -5.8%.

Lifemd, Inc. (LFMDP) reported diluted earnings per share of $0.25 for fiscal year 2025. This represents a 141.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifemd, Inc. (LFMDP) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Lifemd, Inc. (LFMDP) had a gross margin of 85.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Lifemd, Inc. (LFMDP) had an operating margin of -4.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Lifemd, Inc. (LFMDP) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Lifemd, Inc. (LFMDP) has a return on equity of -48.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Lifemd, Inc. (LFMDP) generated $6.4M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Lifemd, Inc. (LFMDP) generated $8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Lifemd, Inc. (LFMDP) had $70.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Lifemd, Inc. (LFMDP) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Lifemd, Inc. (LFMDP) spent $270K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Lifemd, Inc. (LFMDP) had 47M shares outstanding as of fiscal year 2025.

Lifemd, Inc. (LFMDP) had a current ratio of 1.25 as of fiscal year 2025, which is considered adequate.

Lifemd, Inc. (LFMDP) had a debt-to-equity ratio of 2.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Lifemd, Inc. (LFMDP) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Lifemd, Inc. (LFMDP) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Lifemd, Inc. (LFMDP) has an earnings quality ratio of -0.74x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Lifemd, Inc. (LFMDP) has an interest coverage ratio of -5.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Lifemd, Inc. (LFMDP) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top